GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (NAS:ATAI) » Definitions » Current Ratio

ATAI (ATAI Life Sciences NV) Current Ratio : 5.81 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. ATAI Life Sciences NV's current ratio for the quarter that ended in Sep. 2024 was 5.81.

ATAI Life Sciences NV has a current ratio of 5.81. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for ATAI Life Sciences NV's Current Ratio or its related term are showing as below:

ATAI' s Current Ratio Range Over the Past 10 Years
Min: 5.81   Med: 13.43   Max: 32.26
Current: 5.81

During the past 5 years, ATAI Life Sciences NV's highest Current Ratio was 32.26. The lowest was 5.81. And the median was 13.43.

ATAI's Current Ratio is ranked better than
65.47% of 1503 companies
in the Biotechnology industry
Industry Median: 3.69 vs ATAI: 5.81

ATAI Life Sciences NV Current Ratio Historical Data

The historical data trend for ATAI Life Sciences NV's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV Current Ratio Chart

ATAI Life Sciences NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
24.36 8.09 17.92 14.43 9.22

ATAI Life Sciences NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.96 9.22 7.83 6.68 5.81

Competitive Comparison of ATAI Life Sciences NV's Current Ratio

For the Biotechnology subindustry, ATAI Life Sciences NV's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ATAI Life Sciences NV's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ATAI Life Sciences NV's Current Ratio distribution charts can be found below:

* The bar in red indicates where ATAI Life Sciences NV's Current Ratio falls into.



ATAI Life Sciences NV Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

ATAI Life Sciences NV's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=185.592/20.12
=9.22

ATAI Life Sciences NV's Current Ratio for the quarter that ended in Sep. 2024 is calculated as

Current Ratio (Q: Sep. 2024 )=Total Current Assets (Q: Sep. 2024 )/Total Current Liabilities (Q: Sep. 2024 )
=114.074/19.643
=5.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ATAI Life Sciences NV  (NAS:ATAI) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


ATAI Life Sciences NV Current Ratio Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ATAI Life Sciences NV Business Description

Traded in Other Exchanges
Address
Wallstrasse 16, Berlin, BB, DEU, 10179
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Executives
Florian Brand officer: See Remarks C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Srinivas Rao officer: See Remarks C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Sahil Kirpekar officer: Chief Business Officer C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179
Anne Nagengast Johnson officer: Chief Accounting Officer C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179
Apeiron Investment Group Ltd. 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Stephen Bardin officer: Chief Financial Officer C/O ATAI LIFE SCIENCES N.V., KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Gregory L Weaver officer: Chief Financial Officer 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Andrea Heslin Smiley director 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Michael Auerbach director 158 HESTER STREET, APT 7F, NEW YORK NY 10013
Amir H Kalali director 4350 EXECUTIVE DRIVE SUITE 325, SAN DIEGO CA 92121
Christian Angermayer director, 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Rosnay Alexis De director C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Sabrina Martucci Johnson director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Camm director C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Presight Ii, Lp 10 percent owner C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014